For the last two years, the European Medicines Agency has carried out ‘single assessments’ of post-marketing safety reports relating to products with the same active substance.
Previously, such reports had been submitted by drugmakers and reviewed separately.
The EMA has now issued drugmakers with additional guidance and recommendations related to this approach, which is designed to streamline the pharmacovigilance process for generics and biosimilars.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze